{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,2]],"date-time":"2022-04-02T09:06:10Z","timestamp":1648890370579},"reference-count":81,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1007\/s00280-009-0955-3","type":"journal-article","created":{"date-parts":[[2009,3,3]],"date-time":"2009-03-03T11:24:13Z","timestamp":1236079453000},"page":"1-13","source":"Crossref","is-referenced-by-count":9,"title":["Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer"],"prefix":"10.1007","volume":"63","author":[{"given":"Joaquim","family":"Bellmunt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emiliano","family":"Calvo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Castellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel \u00c1ngel","family":"Climent","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilio","family":"Esteban","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Garc\u00eda del Muro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"Gonz\u00e1lez-Larriba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Maroto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Trigo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,3,4]]},"reference":[{"key":"955_CR1","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3322\/CA.2007.0010","volume":"58","author":"A Jemal","year":"2008","unstructured":"Jemal A, Siegel R, Ward E et al (2008) Cancer statistics, 2008. CA Cancer J Clin 58:71\u201396","journal-title":"CA Cancer J Clin"},{"key":"955_CR2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ucl.2004.01.004","volume":"31","author":"R Dhote","year":"2004","unstructured":"Dhote R, Thiounn N, Debre B et al (2004) Risk factors for adult renal cell carcinoma. Urol Clin N Am 31:237\u2013247","journal-title":"Urol Clin N Am"},{"key":"955_CR3","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/jnci\/djh014","volume":"96","author":"P Vineis","year":"2004","unstructured":"Vineis P, Alavanja M, Buffler P et al (2004) Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 96:99\u2013106","journal-title":"J Natl Cancer Inst"},{"key":"955_CR4","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1056\/NEJM200011023431804","volume":"343","author":"WH Chow","year":"2000","unstructured":"Chow WH, Gridley G, Fraumeni JF Jr et al (2000) Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 343:1305\u20131311","journal-title":"N Engl J Med"},{"key":"955_CR5","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1046\/j.1464-410x.2000.00708.x","volume":"86","author":"R Dhote","year":"2000","unstructured":"Dhote R, Pellicer-Coeuret M, Thiounn N et al (2000) Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int 86:20\u201327","journal-title":"BJU Int"},{"issue":"Suppl 10","key":"955_CR6","doi-asserted-by":"crossref","first-page":"x19","DOI":"10.1093\/annonc\/mdl230","volume":"17","author":"J Wagstaff","year":"2006","unstructured":"Wagstaff J (2006) New horizons in the treatment of renal cell cancer. Ann Oncol 17(Suppl 10):x19\u2013x22","journal-title":"Ann Oncol"},{"key":"955_CR7","doi-asserted-by":"crossref","first-page":"667s","DOI":"10.1158\/1078-0432.CCR-06-2231","volume":"13","author":"MB Atkins","year":"2007","unstructured":"Atkins MB, Ernstoff MS, Figlin RA et al (2007) Innovations and challenges in renal cell carcinoma: summary statement from the Second Cambridge Conference. Clin Cancer Res 13:667s\u2013670s","journal-title":"Clin Cancer Res"},{"key":"955_CR8","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1158\/0008-5472.CAN-05-3074","volume":"66","author":"RE Banks","year":"2006","unstructured":"Banks RE, Tirukonda P, Taylor C et al (2006) Genetic and epigenetic analysis of von Hippel\u2013Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancer. Cancer Res 66:2000\u20132011","journal-title":"Cancer Res"},{"key":"955_CR9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/ng0597-68","volume":"16","author":"L Schmidt","year":"1997","unstructured":"Schmidt L, Duh FM, Chen F et al (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet 16:68\u201373","journal-title":"Nat Genet"},{"key":"955_CR10","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1086\/430842","volume":"76","author":"LS Schmidt","year":"2005","unstructured":"Schmidt LS, Nickerson ML, Warren MB et al (2005) Germline BHD-mutation spectrum and phenotype analysis of a large cohort of families with Birt-Hogg-Dube syndrome. Am J Hum Genet 76:1023\u20131033","journal-title":"Am J Hum Genet"},{"key":"955_CR11","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.6004\/jnccn.2006.0089","volume":"4","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Bolger GB, Boston B et al (2006) Kidney cancer. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw 4:1072\u20131081","journal-title":"J Natl Compr Cancer Netw"},{"key":"955_CR12","doi-asserted-by":"crossref","DOI":"10.1007\/978-1-4757-3656-4","volume-title":"AJCC cancer staging handbook: TNM classification of malignant tumors","author":"FL Greene","year":"2002","unstructured":"Greene FL, Page DL, Fleming ID et al (2002) AJCC cancer staging handbook: TNM classification of malignant tumors. Springer, New York"},{"key":"955_CR13","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ctrv.2005.07.009","volume":"31","author":"BJ Drucker","year":"2005","unstructured":"Drucker BJ (2005) Renal cell carcinoma: current status and future prospects. Cancer Treat Rev 31:536\u2013545","journal-title":"Cancer Treat Rev"},{"key":"955_CR14","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0022-5347(01)67599-2","volume":"153","author":"PD Guinan","year":"1995","unstructured":"Guinan PD, Vogelzang NJ, Fremgen AM et al (1995) Renal cell carcinoma: tumor size, stage and survival. Members of the Cancer Incidence and End Results Committee. J Urol 153:901\u2013903","journal-title":"J Urol"},{"key":"955_CR15","doi-asserted-by":"crossref","first-page":"6322S","DOI":"10.1158\/1078-0432.CCR-050003","volume":"10","author":"AC Novick","year":"2004","unstructured":"Novick AC (2004) Laparoscopic and partial nephrectomy. Clin Cancer Res 10:6322S\u20136327S","journal-title":"Clin Cancer Res"},{"key":"955_CR16","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1634\/theoncologist.12-12-1404","volume":"12","author":"LJ Costa","year":"2007","unstructured":"Costa LJ, Drabkin HA (2007) Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies. Oncologist 12:1404\u20131415","journal-title":"Oncologist"},{"key":"955_CR17","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMoa003013","volume":"345","author":"RC Flanigan","year":"2001","unstructured":"Flanigan RC, Salmon SE, Blumenstein BA et al (2001) Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 345:1655\u20131659","journal-title":"N Engl J Med"},{"key":"955_CR18","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/S0140-6736(01)06103-7","volume":"358","author":"GH Mickisch","year":"2001","unstructured":"Mickisch GH, Garin A, van Poppel H et al (2001) Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358:966\u2013970","journal-title":"Lancet"},{"key":"955_CR19","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3322\/canjclin.57.2.112","volume":"57","author":"JA Garcia","year":"2007","unstructured":"Garcia JA, Rini BI (2007) Recent progress in the management of advanced renal cell carcinoma. CA Cancer J Clin 57:112\u2013125","journal-title":"CA Cancer J Clin"},{"key":"955_CR20","doi-asserted-by":"crossref","first-page":"2261","DOI":"10.1200\/JCO.1998.16.6.2261","volume":"16","author":"JP Kavolius","year":"1998","unstructured":"Kavolius JP, Mastorakos DP, Pavlovich C et al (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16:2261\u20132266","journal-title":"J Clin Oncol"},{"key":"955_CR21","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ncpuro0029","volume":"1","author":"P Russo","year":"2004","unstructured":"Russo P (2004) Surgical intervention in patients with metastatic renal cancer: current status of metastasectomy and cytoreductive nephrectomy. Nat Clin Pract Urol 1:26\u201330","journal-title":"Nat Clin Pract Urol"},{"key":"955_CR22","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3816\/CGC.2006.n.042","volume":"5","author":"BI Rini","year":"2006","unstructured":"Rini BI, Shaw V, Rosenberg JE et al (2006) Patients with metastatic renal cell carcinoma with long-term disease-free survival after treatment with sunitinib and resection of residual metastases. Clin Genitourin Cancer 5:232\u2013234","journal-title":"Clin Genitourin Cancer"},{"key":"955_CR23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1464-410X.1973.tb12152.x","volume":"45","author":"R Finney","year":"1973","unstructured":"Finney R (1973) The value of radiotherapy in the treatment of hypernephroma\u2014a clinical trial. Br J Urol 45:258\u2013269","journal-title":"Br J Urol"},{"key":"955_CR24","doi-asserted-by":"crossref","first-page":"277","DOI":"10.3109\/00365597709179965","volume":"11","author":"H Juusela","year":"1977","unstructured":"Juusela H, Malmio K, Alfthan O et al (1977) Preoperative irradiation in the treatment of renal adenocarcinoma. Scand J Urol Nephrol 11:277\u2013281","journal-title":"Scand J Urol Nephrol"},{"key":"955_CR25","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0360-3016(87)90283-5","volume":"13","author":"M Kjaer","year":"1987","unstructured":"Kjaer M, Frederiksen PL, Engelholm SA (1987) Postoperative radiotherapy in stage II and III renal adenocarcinoma. A randomized trial by the Copenhagen Renal Cancer Study Group. Int J Radiat Oncol Biol Phys 13:665\u2013672","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"955_CR26","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3109\/00365598709180784","volume":"21","author":"M Kjaer","year":"1987","unstructured":"Kjaer M, Iversen P, Hvidt V et al (1987) A randomized trial of postoperative radiotherapy versus observation in stage II and III renal adenocarcinoma. A study by the Copenhagen Renal Cancer Study Group. Scand J Urol Nephrol 21:285\u2013289","journal-title":"Scand J Urol Nephrol"},{"key":"955_CR27","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.radonc.2005.03.022","volume":"77","author":"PJ Wersall","year":"2005","unstructured":"Wersall PJ, Blomgren H, Lax I et al (2005) Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 77:88\u201395","journal-title":"Radiother Oncol"},{"key":"955_CR28","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/BLO.0b013e3180616594","volume":"459","author":"LM Reichel","year":"2007","unstructured":"Reichel LM, Pohar S, Heiner J et al (2007) Radiotherapy to bone has utility in multifocal metastatic renal carcinoma. Clin Orthop Relat Res 459:133\u2013138","journal-title":"Clin Orthop Relat Res"},{"key":"955_CR29","first-page":"603","volume":"20","author":"LS Doh","year":"2006","unstructured":"Doh LS, Amato RJ, Paulino AC et al (2006) Radiation therapy in the management of brain metastases from renal cell carcinoma. Oncology (Williston Park) 20:603\u2013613 discussion 613, 616, 619\u2013620 passsim","journal-title":"Oncology (Williston Park)"},{"key":"955_CR30","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1080\/02841860600954875","volume":"45","author":"C Svedman","year":"2006","unstructured":"Svedman C, Sandstrom P, Pisa P et al (2006) A prospective phase II trial of using extracranial stereotactic radiotherapy in primary and metastatic renal cell carcinoma. Acta Oncol 45:870\u2013875","journal-title":"Acta Oncol"},{"key":"955_CR31","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1634\/theoncologist.12-4-465","volume":"12","author":"S Senan","year":"2007","unstructured":"Senan S, Smit EF (2007) Design of clinical trials of radiation combined with antiangiogenic therapy. Oncologist 12:465\u2013477","journal-title":"Oncologist"},{"key":"955_CR32","first-page":"177","volume":"27","author":"RJ Amato","year":"2000","unstructured":"Amato RJ (2000) Chemotherapy for renal cell carcinoma. Semin Oncol 27:177\u2013186","journal-title":"Semin Oncol"},{"key":"955_CR33","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1200\/JCO.2003.02.014","volume":"21","author":"JI Clark","year":"2003","unstructured":"Clark JI, Atkins MB, Urba WJ et al (2003) Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 21:3133\u20133140","journal-title":"J Clin Oncol"},{"key":"955_CR34","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1200\/JCO.2003.02.005","volume":"21","author":"EM Messing","year":"2003","unstructured":"Messing EM, Manola J, Wilding G et al (2003) Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group\/Intergroup trial. J Clin Oncol 21:1214\u20131222","journal-title":"J Clin Oncol"},{"key":"955_CR35","unstructured":"Pizzocaro G, Piva L, Costa A, Silvestrini R (1997) Adjuvant interferon (IFN) to radical nephrectomy in Robson\u2019s stages II and III renal cell cancer (RCC), a multicenter randomized study with some biological evaluations, 1997 ASCO annual meeting, abstract 1132"},{"key":"955_CR36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0140-6736(04)15590-6","volume":"363","author":"D Jocham","year":"2004","unstructured":"Jocham D, Richter A, Hoffmann L et al (2004) Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 363:594\u2013599","journal-title":"Lancet"},{"key":"955_CR37","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/sj.bjc.6604266","volume":"98","author":"E Jonasch","year":"2008","unstructured":"Jonasch E, Wood C, Tamboli P et al (2008) Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98:1336\u20131341","journal-title":"Br J Cancer"},{"key":"955_CR38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(08)60697-2","volume":"372","author":"C Wood","year":"2008","unstructured":"Wood C, Srivastava P, Bukowski R et al (2008) An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial. Lancet 372:145\u2013154","journal-title":"Lancet"},{"key":"955_CR39","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1016\/j.eururo.2006.12.031","volume":"51","author":"A Skolarikos","year":"2007","unstructured":"Skolarikos A, Alivizatos G, Laguna P et al (2007) A review on follow-up strategies for renal cell carcinoma after nephrectomy. Eur Urol 51:1490\u20131500 discussion 1501","journal-title":"Eur Urol"},{"key":"955_CR40","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1097\/00000478-198210000-00007","volume":"6","author":"SA Fuhrman","year":"1982","unstructured":"Fuhrman SA, Lasky LC, Limas C (1982) Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655\u2013663","journal-title":"Am J Surg Pathol"},{"key":"955_CR41","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/j.1464-410X.2007.07006.x","volume":"100","author":"J Sandlund","year":"2007","unstructured":"Sandlund J, Oosterwijk E, Grankvist K et al (2007) Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100:556\u2013560","journal-title":"BJU Int"},{"key":"955_CR42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0090-4295(01)01207-9","volume":"58","author":"O Yaycioglu","year":"2001","unstructured":"Yaycioglu O, Roberts WW, Chan T et al (2001) Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 58:141\u2013145","journal-title":"Urology"},{"key":"955_CR43","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0022-5347(05)66077-6","volume":"166","author":"MW Kattan","year":"2001","unstructured":"Kattan MW, Reuter V, Motzer RJ et al (2001) A postoperative prognostic nomogram for renal cell carcinoma. J Urol 166:63\u201367","journal-title":"J Urol"},{"key":"955_CR44","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/S0022-5347(05)64153-5","volume":"168","author":"I Frank","year":"2002","unstructured":"Frank I, Blute ML, Cheville JC et al (2002) An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol 168:2395\u20132400","journal-title":"J Urol"},{"key":"955_CR45","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.2001.19.6.1649","volume":"19","author":"A Zisman","year":"2001","unstructured":"Zisman A, Pantuck AJ, Dorey F et al (2001) Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 19:1649\u20131657","journal-title":"J Clin Oncol"},{"key":"955_CR46","doi-asserted-by":"crossref","first-page":"3316","DOI":"10.1200\/JCO.2004.09.104","volume":"22","author":"JJ Patard","year":"2004","unstructured":"Patard JJ, Kim HL, Lam JS et al (2004) Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 22:3316\u20133322","journal-title":"J Clin Oncol"},{"key":"955_CR47","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1111\/j.1464-410X.2003.04505.x","volume":"92","author":"L Cindolo","year":"2003","unstructured":"Cindolo L, de la Taille A, Messina G et al (2003) A preoperative clinical prognostic model for non-metastatic renal cell carcinoma. BJU Int 92:901\u2013905","journal-title":"BJU Int"},{"key":"955_CR48","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/cncr.21331","volume":"104","author":"L Cindolo","year":"2005","unstructured":"Cindolo L, Patard JJ, Chiodini P et al (2005) Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 104:1362\u20131371","journal-title":"Cancer"},{"key":"955_CR49","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(98)03544-2","volume":"353","author":"A Ritchie","year":"1999","unstructured":"Ritchie A, Griffiths G, Parmar M, for the MRC Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 353:14\u201317","journal-title":"Lancet"},{"key":"955_CR50","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1200\/JCO.1995.13.3.688","volume":"13","author":"G Fyfe","year":"1995","unstructured":"Fyfe G, Fisher RI, Rosenberg SA et al (1995) Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13:688\u2013696","journal-title":"J Clin Oncol"},{"key":"955_CR51","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JCO.2005.03.206","volume":"23","author":"DF McDermott","year":"2005","unstructured":"McDermott DF, Regan MM, Clark JI et al (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23:133\u2013141","journal-title":"J Clin Oncol"},{"key":"955_CR52","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1200\/JCO.2003.02.122","volume":"21","author":"JC Yang","year":"2003","unstructured":"Yang JC, Sherry RM, Steinberg SM et al (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 21:3127\u20133132","journal-title":"J Clin Oncol"},{"key":"955_CR53","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1200\/JCO.1989.7.4.486","volume":"7","author":"KA Margolin","year":"1989","unstructured":"Margolin KA, Rayner AA, Hawkins MJ et al (1989) Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines. J Clin Oncol 7:486\u2013498","journal-title":"J Clin Oncol"},{"key":"955_CR54","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1002\/cncr.23056","volume":"110","author":"S Negrier","year":"2007","unstructured":"Negrier S, Perol D, Ravaud A et al (2007) Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer 110:2468\u20132477","journal-title":"Cancer"},{"key":"955_CR55","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1200\/JCO.2002.20.1.289","volume":"20","author":"RJ Motzer","year":"2002","unstructured":"Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289\u2013296","journal-title":"J Clin Oncol"},{"key":"955_CR56","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.1999.17.8.2530","volume":"17","author":"RJ Motzer","year":"1999","unstructured":"Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17:2530\u20132540","journal-title":"J Clin Oncol"},{"key":"955_CR57","doi-asserted-by":"crossref","first-page":"6310S","DOI":"10.1158\/1078-0432.CCR-050000","volume":"10","author":"RM Bukowski","year":"2004","unstructured":"Bukowski RM, Negrier S, Elson P (2004) Prognostic factors in patients with advanced renal cell carcinoma: development of an international kidney cancer working group. Clin Cancer Res 10:6310S\u20136314S","journal-title":"Clin Cancer Res"},{"key":"955_CR58","first-page":"327","volume":"9","author":"DB Mendel","year":"2003","unstructured":"Mendel DB, Laird AD, Xin X et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship. Clin Cancer Res 9:327\u2013337","journal-title":"Clin Cancer Res"},{"key":"955_CR59","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","volume":"24","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Michaelson MD, Redman BG et al (2006) Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24:16\u201324","journal-title":"J Clin Oncol"},{"key":"955_CR60","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","volume":"295","author":"RJ Motzer","year":"2006","unstructured":"Motzer RJ, Rini BI, Bukowski RM et al (2006) Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295:2516\u20132524","journal-title":"JAMA"},{"key":"955_CR61","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","volume":"356","author":"RJ Motzer","year":"2007","unstructured":"Motzer RJ, Hutson TE, Tomczak P et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356:115\u2013124","journal-title":"N Engl J Med"},{"issue":"May 20 suppl","key":"955_CR62","doi-asserted-by":"crossref","first-page":"abstr 5024","DOI":"10.1200\/jco.2008.26.15_suppl.5024","volume":"26","author":"RA Figlin","year":"2008","unstructured":"Figlin RA, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, N\u00e9grier S, Huang X, Kim ST, Chen I, Motzer RJ (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol, vol 26 (May 20 suppl), abstr 5024","journal-title":"J Clin Oncol"},{"key":"955_CR63","first-page":"511","volume":"25","author":"RA Hilger","year":"2002","unstructured":"Hilger RA, Scheulen ME, Strumberg D (2002) The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie 25:511\u2013518","journal-title":"Onkologie"},{"key":"955_CR64","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1093\/jjco\/hym095","volume":"37","author":"H Akaza","year":"2007","unstructured":"Akaza H, Tsukamoto T, Murai M et al (2007) Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 37:755\u2013762","journal-title":"Jpn J Clin Oncol"},{"key":"955_CR65","doi-asserted-by":"crossref","unstructured":"Bukowski RM, Eisen T, Szczylik C, Stadler WM, Simantov R, Shan M, Elting J, Pena C, Escudier B (2007) Final results of the randomized phase III trial of sorafenib in advanced renal cell carcinoma: survival and biomarker analysis. In: 2007 ASCO annual meeting proceedings, part I. J Clin Oncol, vol 25, no. 18S (June 20 supplement), abstr 5023","DOI":"10.1200\/jco.2007.25.18_suppl.5023"},{"key":"955_CR66","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","volume":"356","author":"B Escudier","year":"2007","unstructured":"Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125\u2013134","journal-title":"N Engl J Med"},{"key":"955_CR67","doi-asserted-by":"crossref","unstructured":"Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K, Escudier B (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. In: 2007 ASCO annual meeting proceedings, part I. J Clin Oncol, vol 25, no. 18S (June 20 supplement), abstr 5025","DOI":"10.1200\/jco.2007.25.18_suppl.5025"},{"key":"955_CR68","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","volume":"23","author":"BI Rini","year":"2005","unstructured":"Rini BI, Small EJ (2005) Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23:1028\u20131043","journal-title":"J Clin Oncol"},{"key":"955_CR69","first-page":"4593","volume":"57","author":"LG Presta","year":"1997","unstructured":"Presta LG, Chen H, O\u2019Connor SJ et al (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57:4593\u20134599","journal-title":"Cancer Res"},{"key":"955_CR70","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.1200\/JCO.2007.11.5154","volume":"25","author":"RM Bukowski","year":"2007","unstructured":"Bukowski RM, Kabbinavar FF, Figlin RA et al (2007) Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer. J Clin Oncol 25:4536\u20134541","journal-title":"J Clin Oncol"},{"key":"955_CR71","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P et al (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370:2103\u20132111","journal-title":"Lancet"},{"key":"955_CR72","unstructured":"Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena D, Ou S, Taylor J, Tanguay S, Dutcher J, Small EJ (2008) CALGB 90206: a phase III trial of bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in metastatic renal cell carcinoma, 2008 genitourinary cancers symposium, abstract no. 350"},{"key":"955_CR73","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","volume":"349","author":"JC Yang","year":"2003","unstructured":"Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427\u2013434","journal-title":"N Engl J Med"},{"key":"955_CR74","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1093\/annonc\/mdn161","volume":"19","author":"B Melichar","year":"2008","unstructured":"Melichar B, Koralewski P, Ravaud A et al (2008) First-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinoma. Ann Oncol 19:1470\u20131476","journal-title":"Ann Oncol"},{"key":"955_CR75","doi-asserted-by":"crossref","first-page":"7004","DOI":"10.1128\/MCB.22.20.7004-7014.2002","volume":"22","author":"CC Hudson","year":"2002","unstructured":"Hudson CC, Liu M, Chiang GG et al (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22:7004\u20137014","journal-title":"Mol Cell Biol"},{"key":"955_CR76","doi-asserted-by":"crossref","first-page":"5549","DOI":"10.1158\/0008-5472.CAN-05-2825","volume":"66","author":"D Del Bufalo","year":"2006","unstructured":"Del Bufalo D, Ciuffreda L, Trisciuoglio D et al (2006) Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus. Cancer Res 66:5549\u20135554","journal-title":"Cancer Res"},{"key":"955_CR77","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","volume":"22","author":"MB Atkins","year":"2004","unstructured":"Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909\u2013918","journal-title":"J Clin Oncol"},{"key":"955_CR78","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","volume":"356","author":"G Hudes","year":"2007","unstructured":"Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271\u20132281","journal-title":"N Engl J Med"},{"issue":"May 20 suppl","key":"955_CR79","doi-asserted-by":"crossref","first-page":"abstr 5113","DOI":"10.1200\/jco.2008.26.15_suppl.5113","volume":"26","author":"J Jac","year":"2008","unstructured":"Jac J, Amato RJ, Giessinger S, Saxena S, Willis JP (2008) A phase II study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic renal cell carcinoma which has progressed on tyrosine kinase inhibition therapy. J Clin Oncol 26(May 20 suppl):abstr 5113","journal-title":"J Clin Oncol"},{"issue":"May 20 suppl","key":"955_CR80","doi-asserted-by":"crossref","first-page":"abstr LBA5026","DOI":"10.1200\/jco.2008.26.15_suppl.lba5026","volume":"26","author":"RJ Motzer","year":"2008","unstructured":"Motzer RJ, Escudier B, Oudard S, Porta C, Hutson TE, Bracarda S, Hollaender N, Urbanowitz G, Kay A, Ravaud A (2008) RAD001 vs placebo in patients with metastatic renal cell carcinoma (RCC) after progression on VEGFr-TKI therapy: results from a randomized, double-blind, multicenter phase-III study. J Clin Oncol 26(May 20 suppl):abstr LBA5026","journal-title":"J Clin Oncol"},{"key":"955_CR81","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2004.06.132","volume":"22","author":"RJ Motzer","year":"2004","unstructured":"Motzer RJ, Bacik J, Schwartz LH et al (2004) Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22:454\u2013463","journal-title":"J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-0955-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-009-0955-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-009-0955-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T08:04:50Z","timestamp":1589616290000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-009-0955-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":81,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["955"],"URL":"https:\/\/doi.org\/10.1007\/s00280-009-0955-3","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3]]}}}